

Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere without the permission of the Author.

Gastrointestinal Endogenous Proteins as a Source of Bioactive Peptides

Doctor of Philosophy

In

Nutritional Sciences

At

Riddet Institute, Massey University,

Palmerston North

New Zealand

Prasannalakshmi Acharya

2016



Abstract

Gastrointestinal endogenous proteins (GEP) were investigated as a source of bioactive peptides. *In silico* and *in vitro* methods were used singly or in combination to study GEP-derived peptides after simulated digestion. The presence of bioactive peptides after *in vivo* digestion was determined using a porcine model. Bioactivity of the peptides was assessed using selected *in vitro* bioactivity assays, and peptides were characterised using sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and mass spectrometry.

In the *in silico* study, twenty six different GEP and seven dietary proteins were subjected to simulated *in silico* gastrointestinal (SIGIT) digestion. The predicted resultant peptides possessing amino acid sequences identical to those of known bioactive peptides were identified by screening them against an online database of bioactive peptides (BIOPEP). The predicted number of bioactive peptides released after the SIGIT digestion of GEP ranged from 1 (secretin) to 39 (mucin-5AC), while those for dietary proteins ranged from 1 (gliadin) to 55 (myosin). Angiotensin-I-converting enzyme (ACE-I) inhibitory peptide sequences were found in abundance in both GEP and dietary proteins. The GEP mucin-5AC and the dietary protein myosin were predicted to release the highest number of ACE-I inhibitory peptides (38 and 49 peptides respectively), and were found to be comparable in their potential to release ACE-I inhibitory peptides.

Following SIGIT digestion of eleven representative GEP, nineteen novel GEP-derived peptide sequences were selected by applying quantitative structure-activity relationship rules, and were chemically synthesised. Two novel peptides with the

Abstract

amino acid sequences RPCF and MIM, showing dipeptidyl peptidase IV (DPP-IV) inhibitory activity and five novel antioxidant (2,2-diphenyl-1-picrylhydrazyl (DPPH)- inhibitory and, or ferric reducing antioxidant power (FRAP) activity) peptides with amino acid sequences CCK, RPCF, CRPK, QQCP and DCR were identified. These results indicate that GEP may contain novel bioactive peptide sequences.

The potential release of bioactive peptides, from four GEP (trypsin, lysozyme, mucin, and serum albumin) and a dietary protein (chicken albumin), in the gastrointestinal tract (GIT) was investigated using an *in vitro* digestion model. The *in vitro* digests were screened for ACE-I-, renin-, platelet-activating factor acetylhydrolase (PAF-AH)-, and DPP-IV-inhibition, and antioxidant activity. All four *in vitro* GEP digests showed ACE-I inhibition comparable to that of the positive control captopril. In comparison to the unfractionated digests, the enriched fractions (<3 and <10 kDa) of lysozyme and serum albumin showed greater renin-, PAF-AH-, and DPP-IV-inhibition, and antioxidant potential. Over 190 peptide sequences were identified from these fractions using mass spectrometry.

Stomach chyme (SC) and jejunal digesta (JD) were collected from growing pigs that were fed a protein-free diet for a period of 3 days. The peptides extracted from SC and JD samples were characterized by SDS-PAGE, and their ACE-I-, DPPH-, and microsomal lipid peroxidation (MLP)- inhibition, FRAP activity determined. Potential bioactive peptides responsible for bioactivity were identified using mass spectrometry. SDS-PAGE analysis showed that all of the samples contained a heterogeneous mixture of peptides. Porcine JD samples inhibited ACE-I and DPPH, while SC samples inhibited MLP. Characterization studies identified over 180

peptide sequences from the enriched fractions of SC and JD samples that showed the highest activity. Further, a porcine serum albumin peptide sequence (FAKTCVADESAENCCKS) was found to be a sub-sequence of a larger sequence identified in the *in vitro* digest of human serum albumin. There was considerable inter-animal variation for the bioactivities. This may be attributed to sampling effects and, or natural variations in the gut contents, thus underlining the complexity involved in *in vivo* release of bioactive peptides.

Together, the results indicate: 1) GEP contain abundant encrypted bioactive peptide sequences; 2) GEP-derived bioactive peptides display a range of bioactivities; 3) GEP-derived bioactive peptides are released during gastrointestinal digestion in pigs; 4) GEP may contain numerous novel bioactive peptide sequences encoded within their primary sequence.

In conclusion, the evidence reported here suggests that, like the dietary proteins, GEP are also a potentially rich source of exogenously-derived bioactive peptides in the gastrointestinal tract. Beyond their primary functions, GEP may act as an important cryptomic source of bioactive peptides, given that the amount of GEP secreted into the gut is equal to or greater than the dietary protein ingested per day, and that up to 80% of GEP are known to be digested.

Acknowledgements

First and foremost, I want to thank my primary supervisor, Distinguished Professor Paul J. Moughan. It has been an honour to be his Ph.D student. My deepest gratitude to him for all the opportunities to carry out my research and further my thesis. I have learnt some truly important aspects of human nutrition, scientific studies and writing from him. Most importantly, I have learnt from him that it is crucial to study pieces of information that are often ignored, because that is where original ideas emerge from.

I also wish to place on record my sincere gratitude for Dr. Shane M. Rutherford and Dr. Carlos A. Montoya, my former co-supervisor and co-supervisor, for helping me understand the basics of proteins and peptides, for challenging and enriching my ideas, and for their critical inputs to this dissertation.

I would like thank my co-supervisor, Dr. Maria Hayes, Teagasc Ashtown Food Research Centre, Dublin. I am extremely grateful to her for the opportunity to collaborate for this project, and for her kind concern for my wellbeing while I was in Ireland. There aren't enough words to describe the "grand" ten months that I spent working in her laboratory in Teagasc. She is my (s)hero!

I am grateful for the Riddet Institute Scholarship that I received during my studies, and for the kind support from the Riddet Institute for forging a collaboration and continuing this work at the Irish Agriculture and Food Development Authority, Teagasc. I acknowledge the financial support from the Centre of Research Excellence (CoRE) fund, the Tertiary Education Commission and the Ministry of Education, New Zealand.

Acknowledgements

I also acknowledge the Massey University Human Ethics Committee for the approval of the pig trials (Ethics No. MUAEC 11/31), presented in Chapter 6.

I would like to thank Distinguished Professor Harjinder Singh for his concern for my wellbeing, and constant encouragement. I also wish to thank Dr. Simon Loveday for his interest and helpful discussions. I am grateful to the administrative staff at the Riddet Institute for facilitating my research, a big thank you to Mrs. Ansley Te Hiwi, Mrs. Terri Palmer and Ms. Felicia Stibbards, Mr. John Henley-King, Ms. Paula McCool and Mr. Matt Levin for their help, and also to Ms. Willi Stevenson-Wright, who was with the Riddet Institute during the beginning of this project.

The initial work of this dissertation, that paved the way for future experiments, was conducted in the Riddet Institute Laboratory. I would like to thank Ms. Janiene Gilliland and Mr. Chris Hall for all their help in the lab. I also acknowledge the support I received from Dr. Warren Miner-Williams, Mr. Russel Richardson, Ms. Maggie Zhou, Mr. Trevor Loo, Ms. Chanapha Sawatdeenaruenat, Mrs. Shampa De, Dr. Xiang-Qian Zhu and Jian Cui. Thanks are also due to my fellow labmates in Riddet, Ms. Natascha Stroebinger, Mr. Mallesh Peram, Mr. Ajitpal Purba, Mrs. Nimmi Taneja, Dr. Amit Taneja, Ms. Diana Carbrera, Dr. Sylvia Chung Chun Lam, Dr. Vikas Mittal and Dr. Anant Dave.

The later part of this project was carried out in the Teagasc Food Research Centre in Co. Dublin, Ireland. A huge thanks to my labmates there, Mr. Tomas Lafarga, Dr. Marco A. Garcia Vaquero, Dr. Rahul Sharma, Mrs. Vibha Sharma, Dr. Carlos Alvarez Garcia, Dr. Ciaran Fitzgerald, and Ms. Dara Kirke for contributing immensely to my personal and professional time at Teagasc. I wish to acknowledge

Dr. Brijesh Tiwari for his kind concern for my wellbeing during my stay in Ashtown.

I owe a debt of gratitude to the following people who facilitated my research:

- Thanks to Professor Marlena Kruger, Professor Manohar Garg, and Dr. Nicole Roy for their suggestions and insights in planning of bioactivity studies.
- Thanks to Dr. Tom Beresford, for helping with the Riddet-Teagasc collaboration and his constant encouragement.
- A huge thank you to Ms. Paula O' Connor, Teagasc Food Research Centre, Moorepark, Fermoy, Co. Cork for her kind assistance in synthesis of peptides for the work described in Chapter 4.
- A special thanks to Dr. Song Miao, Senior Research Officer, Teagasc Food Research Centre, Moorepark, Fermoy, Co. Cork for his kind help in allowing me to conduct my gel electrophoresis experiments in his laboratory.
- I am especially grateful to Ms. Leticia Mora, Instituto de Agroquímica y Tecnología de Alimentos (CSIC), Valencia, Spain, for her help with the peptide sequencing work.
- Thanks are also due to the reviewers of my peer-reviewed publications who have contributed to this work by the way of their critical inputs, appreciation and comments.
- Sincere thanks to Dr. Anwesha Sarkar (University of Leeds, the UK) for her interest in my project and for the motivation.

Acknowledgements

A million thanks to all of my wonderful friends in Dublin, Patricia, Teresa, Linda, Miriam, Kevin, Don, Jimmy, Sam and Richard. They have kept me afloat, and cheerful all through the final year of my studies. A special thanks to Patricia, her small gestures, flowers and lovely cupcakes always lifted my spirits and gave me new energy! Thank you to Rahul Sir and Vibha Ma'am, for being who they are, I am extremely lucky to have met them there in Curragh Hall! Joe and Ann Roche from Kilworth, Co. Cork, Ireland deserve a special mention for being a source of constant encouragement during my stay in Ireland. Go raibh maith agaibh!

In Ireland, I also met a superwoman Monika Kandalova, and a superman Petr Stefko, and their two daughters Nina Emily Stefko and Nela Zoey Stefko, who are both happiness personified. From starting out as flatmates to becoming the best of friends, the time we spent together will be etched on my mind forever. With “five little speckled frogs” playing in the background, and little Nina and Nela by my side, thesis writing became a lot less taxing! Thanks a tonne to Anna Kandalova Ma'am, she is one of the most inspirational and beautiful women I know. Thanks also to Ms. Alena Lanikova, for her kind concern for me during my stay in Ashtown. A heartfelt d'akujem to all of them.

I acknowledge the emotional support of my close friends in India, New Zealand and Canada who contributed to this work by keeping me motivated. Thanks to the Darjis in Vidyanagar, the Patels in Anand, especially Vina Masi and Falguni Bhabhi. Huge thanks to Shaerii and Pankaj, Dipanwita and Sumon, and Dongfang and Qing for all their support.

Lastly, I wish to thank my family for all their love and encouragement. Thank you to Ma, Dad, Dadaji and Priyanka, for their affection and for being so kind, they have,

for me, made the word in-laws obsolete! Thank you to my Amma and Nanna, who are my best friends, and my biggest blessing, for they never stopped me from being a madcap science lover, right from allowing me to keep beetles as pets, to encouraging me to pursue nutrition studies. Everything I am today, I owe it to them. Thank you to Anant, my biggest critic and supporter- rolled into one, I believe that he being my husband is a result of some good karma on my part! He has turned the asadhya (impossible) into sadhya (possible), and has been the anantadrishti (vision) that helped me see the positive in everything that came my way during the last 5 years.

Contents

Abstract	I
Acknowledgements	V
Abbreviations	XIX
List of Figures	XXI
List of Tables	XXVII
List of Publications	XXXI
1. Introduction	1
2. Review of Literature	7
2.1. Introduction	8
2.1.1. <i>Classification of bioactive peptides</i>	8
2.2. GIT: A system of peptide-mediated physiological regulation	14
2.2.1. <i>Immunomodulatory system</i>	14
2.2.2. <i>GIT microbiota</i>	16
2.2.3. <i>Regulatory peptides of the enteric nervous system (ENS)</i>	17
2.2.4. <i>The Renin Angiotensin Aldosterone System (RAAS)</i>	18
2.2.5. <i>Peptide-mediated antioxidant activity</i>	21
2.2.6. <i>Peptide-mediated inhibition of advanced glycation end products</i>	23
2.3. Food protein-derived ExBP	25
2.4. GEP: An unexplored source of ExBP	31

Contents

2.4.1. Major GEP secretions	31
2.4.2. Other GEP proteins	36
2.4.3. Non-secretory components contributing to GEP	37
2.4.4. Effect of dietary nutrients on GEP secretion.....	39
2.5. Current strategies for the investigation of bioactive peptides.....	43
2.5.1. In silico investigation of bioactive peptides	43
2.5.2. In vitro investigation of bioactive peptides	45
2.5.3. In vivo investigation of bioactive peptides	47
2.6. Objectives	50
2.6.1. Experimental approach	51
2.6.2. Experimental techniques	52
3. Gastrointestinal Endogenous Proteins as a Source of Bioactive Peptides - An In silico Study.....	55
3.1. Abstract.....	56
3.2. Introduction.....	57
3.3. Materials and Methods.....	59
3.3.1. Materials.....	59
3.3.2. Prediction of the total number of bioactive peptide sequences present in the intact gut endogenous and dietary proteins	62
3.3.3. Prediction of the total number of bioactive peptides to be released from the digestion of GEP.....	64
3.4. Results.....	65

3.4.1. <i>The total number and frequency (A₀) of bioactive peptide sequences within the amino acid sequence of intact gut endogenous proteins and intact dietary proteins</i>	65
3.4.2. <i>Predicted number and frequency (AD) of bioactive peptides released after gastric digestion of dietary proteins and gut endogenous proteins based on an in silico simulation.....</i>	76
3.4.3. <i>Predicted number and frequency (AD) of bioactive peptides released after gastric and small intestinal digestion of dietary proteins and gut endogenous proteins based on an in silico simulation</i>	80
3.4.4. <i>Predicted number and frequency (AD) of bioactive peptide sequences released after small intestinal digestion of gut endogenous proteins secreted in the small intestine based on an in silico simulation</i>	85
3.5. Discussion.....	88
4. Novel Dipeptidyl Peptidase IV Inhibitory and Antioxidant Peptides Derived from Human Gastrointestinal Endogenous Proteins	101
4.1. Abstract.....	102
4.2. Introduction	102
4.3. Materials and Methods	104
4.3.1. <i>Materials and Reagents</i>	104
4.3.2. <i>Gastrointestinal endogenous proteins (GEP)</i>	105
4.3.3. <i>Preliminary in silico analysis</i>	105
4.3.4. <i>Chemical synthesis of selected peptides.....</i>	108
4.3.5. <i>DPP-IV inhibition</i>	109

Contents

4.3.6. DPPH inhibition.....	110
4.3.7. FRAP bioassay.....	110
4.3.8. Statistical analysis.....	111
4.4. Results.....	111
4.5. Discussion.....	125
5. Gastrointestinal Endogenous Protein-Derived Bioactive Peptides: An <i>in vitro</i> Study of Their Gut Modulatory Potential	141
5.1. Abstract.....	142
5.2. Introduction.....	143
5.3. Materials and Methods.....	145
5.3.1. Materials and Reagents.....	145
5.3.2. Simulated gastrointestinal digestion of selected gastrointestinal endogenous proteins (GEP) and a food protein comparator.....	146
5.3.3. Total protein analysis.....	149
5.3.4. Tris-tricine sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) analysis.....	149
5.3.5. ACE-I inhibition assay.....	150
5.3.6. Renin inhibition assay.....	150
5.3.7. PAF-AH inhibition assay.....	151
5.3.8. DPP-IV inhibition.....	151
5.3.9. 2,2'-Azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS)-based total antioxidant capacity (ABTS-TAC) assay.....	151

5.3.10. DPPH inhibition	152
5.3.11. Electrospray ionization time of flight mass spectrometry (ESI-TOF MS) Characterisation of peptides present in the most active fractions.....	152
5.4. Results	154
5.4.1. Characterization of digests by tris-tricine SDS-PAGE.....	154
5.4.2. Angiotensin-I converting enzyme (ACE-I) inhibition by digests and enriched fractions	156
5.4.3. Renin inhibition by digests and enriched fractions.....	159
5.4.4. Platelet-activating factor-acetylhydrolase (PAF-AH) inhibition by digests and enriched fractions	161
5.4.5. Dipeptidyl peptidase-iv inhibitory (DPP-IV) inhibition by digests and enriched fractions	163
5.4.6. 2,2'-Azino-bis-3-ethylbenzthiazoline-6-sulphonic acid total antioxidant capacity (ABTS-TAC) of digests and enriched fractions	165
5.4.7. DPPH inhibition by digests and enriched fractions	167
5.4.8. Electrospray ionisation time of flight mass spectrometry (ESI-TOF-MS) characterisation of peptides.....	169
5.5. Discussion.....	183
6 Identification of Bioactive Peptides Derived from the Gastrointestinal Endogenous Proteins of Growing Pigs	193
6.1 Abstract.....	194
6.2 Introduction	195

Contents

6.3	Materials and methods	197
6.3.1	<i>Materials and Reagents</i>	197
6.3.2	<i>Test diet</i>	197
6.3.3	<i>Experimental design and sample collection</i>	199
6.3.4	<i>Ammonium sulphate precipitation of proteins</i>	200
6.3.5	<i>Total protein analysis</i>	200
6.3.6	<i>Tris-tricine sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) analysis</i>	200
6.3.7	<i>ACE-I inhibition assay</i>	201
6.3.8	<i>FRAP value</i>	201
6.3.9	<i>DPPH inhibition</i>	201
6.3.10	<i>MLP inhibition</i>	202
6.3.11	<i>Electrospray ionization time-of-flight liquid chromatography tandem mass spectrometry (ESI-TOF LC-MS/MS)-based characterisation of peptides</i>	203
6.3.12	<i>Data analysis</i>	205
6.4	Results	207
6.4.1	<i>SDS-PAGE analysis</i>	207
6.4.2	<i>ACE-I inhibition</i>	209
6.4.3	<i>Antioxidant potential</i>	210
6.4.4	<i>ESI-TOF LC-MS/MS characterisation of peptide sequences</i>	213
6.5	Discussion	237

7. Overall Conclusions and Avenues for Future Work.....	245
7.1. Introduction	246
7.2. Summary of results.....	246
7.2.1. <i>In silico</i> approach to identify potential bioactive sequences	246
7.2.2. Identification of novel bioactive peptides using <i>in silico</i> digestion, <i>de novo</i> chemical synthesis and <i>in vitro</i> bioactivity assays	248
7.2.3. GEP-derived bioactive peptides: an <i>in vitro</i> digestion study	249
7.2.4. Identifying potential bioactive peptides from porcine GEP: an <i>in vivo</i> study.....	250
7.3. General discussion of results	252
7.3.1. Classification of bioactive peptides	252
7.3.2. Bioactive potential of GEP is comparable to that of dietary proteins.	253
7.3.3. Digestion of GEP may generate numerous peptides with multiple bioactivities and, or novel sequences.....	255
7.3.4. Generation of bioactive peptides from GEP in <i>in vivo</i> systems.....	259
7.3.5. Gut microbiota influences generation of bioactive peptides	260
7.3.6. Epithelial cells as a source of bioactive peptides in the GIT.....	262
7.3.7. Structural aspects of proteins/peptides governing digestion and subsequent bioactivity.....	262
7.3.8. Safety and toxicity of GEP-derived bioactive peptides.....	265
7.3.9. Some important considerations in the study of GEP- and dietary protein-derived bioactive peptides.....	265

Contents

7.4. Conclusions..... 267

7.5. Avenues for further work..... 268

8. Bibliography 271

9. Appendices..... 327

9.1. Statements of contribution to doctoral thesis containing publications 327

9.2. Copyright permissions for adaptations of publications into thesis chapters. 329

9.3. Copies of publications..... 331

Abbreviations

ABTS: 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid)

ACE-I: Angiotensin-I-converting enzyme

CaMPDE: Cyclic nucleotide phosphodiesterase 1

DPPH 2,2-Diphenyl-1-picrylhydrazyl

DPP-IV: Dipeptidyl peptidase IV

ENL: Endogenous nitrogen losses

ENS: Enteric nervous system

ESI-TOF LC-MS/MS: Electrospray ionization time-of-flight liquid chromatography tandem mass spectrometry

ESI-TOF MS: Electrospray ionization time-of-flight mass spectrometry

ExBP: Exogenous bioactive peptides

FAO (UN FAO): Food and agriculture organisation of the United Nations

FRAP Ferric reducing antioxidant power

GALT: Gut-associated lymphoid tissue

GEP: Gut endogenous proteins

GIT: Gastrointestinal tract

GLP-2: Glucagon-like peptide-2

Abbreviations

MAFP: Methyl arachidonyl fluorophosphate

MLP inhibition: Microsomal lipid peroxidation inhibition

MWCO: Molecular weight cut-off

NOD: Nucleotide-binding oligomerization domain-like receptors

PAF-AH: Platelet-activating factor acetylhydrolase

QS: Quorum sensing

QSAR: Quantitative structure-activity relationship

RAAS: Renin angiotensin aldosterone system

RFU: Relative fluorescence units

SDS-PAGE: Sodium dodecyl sulphate polyacrylamide gel electrophoresis

SIGIT digestion: Simulated *in silico* gastrointestinal digestion

TEnBP: Truly endogenous bioactive peptides

WPI: Whey protein isolate

List of Figures

Figure 1.1 Overview of chapters in the dissertation.....	5
Figure 2.1 Schematic representation of the types of bioactive peptides that are known to date. The bioactive peptides derived in the body have been grouped as the truly endogenous bioactive peptides (TEBP), while those generated in the GIT lumen are grouped as exogenous bioactive peptides (ExBP).	13
Figure 2.2 The GIT: a complex system relating to numerous regulatory systems ...	15
Figure 2.3 The potential role of cryptome-derived bioactive peptides in the Renin-Angiotensin-Aldosterone System (RAAS).....	19
Figure 2.4 The major contributors to the potential gut cryptome.....	33
Figure 4.1 Schematic representation of the combination of methodologies used for discovery and generation of dipeptidyl peptidase IV (DPP-IV) inhibitory and antioxidant peptides from human gastrointestinal endogenous proteins (GEP).	107
Figure 4.2 The <i>in vitro</i> DPP-IV inhibitory activity (mean \pm SD) of select chemically synthesised peptides tested at a sample concentration of 1 mg/mL. Sitagliptin was used as a positive control and was also tested at a concentration of 100 μ M.	121
Figure 4.3 The <i>in vitro</i> DPPH inhibition activity (mean \pm SD) of selected peptides tested at a concentration of 1 mg/mL. Resveratrol was used as a positive control and was also tested at a concentration of 1 mg/mL.....	123

Figure 4.4 Mean FRAP values (mean \pm SD) of selected synthetic peptides. The values are expressed as the Trolox equivalents (μ M per mg of peptide).

..... 125

Figure 5.1 The *in vitro* experimental design and methodologies used to study the angiotensin-I converting enzyme (ACE-I), renin, Platelet-activating factor-acetylhydrolase (PAF-AH) and dipeptidyl peptidase IV (DPP-IV) inhibition, and Total antioxidant capacity by 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) and 2,2-diphenyl -1-picrylhydrazyl (DPPH) inhibition based antioxidant activity of the gastric and small intestinal hydrolysates and the small intestinal <10 and <3 kDa fractions of gastrointestinal endogenous proteins porcine trypsin, porcine salivary mucin, human recombinant lysozyme and serum albumin, and food protein chicken albumin. SDS-PAGE: Tris-tricine sodium dodecyl sulphate polyacrylamide gel electrophoresis; ESI-TOF MS/MS: Electrospray ionization time of flight mass spectrometry..... 148

Figure 5.2 Tris-tricine SDS-PAGE, of the *in vitro* gastric and small intestinal digests of the gastrointestinal endogenous proteins, porcine trypsin (TRYP), human lysozyme (LYS), porcine salivary mucin (MUC) and human serum albumin (SA), and dietary protein chicken albumin (CA) conducted under reducing conditions. Each protein was analyzed prior to hydrolysis (U) and after gastric (G) and small intestinal digestion (G + SI)..... 156

Figure 5.3 Angiotensin-I converting enzyme (ACE-I) inhibition by (A) gastric (G) and small intestinal digests (G + SI) of the gastrointestinal endogenous proteins, porcine trypsin (TRYP), human lysozyme (LYS), porcine

salivary mucin (MUC) and human serum albumin (SA), and dietary protein chicken albumin (CA); and (B) <10 and <3 kDa fractions of the small intestinal digests. All of the samples and the positive control captopril were tested at the concentration of 1 mg/mL.158

Figure 5.4 Renin inhibition by (A) gastric (G) and small intestinal digests (G + SI) of the gastrointestinal endogenous proteins, porcine trypsin (TRYP), human lysozyme (LYS), porcine salivary mucin (MUC) and human serum albumin (SA), and dietary protein chicken albumin (CA); and (B) <10 and <3 kDa fractions of the small intestinal digests. All of the samples were tested at the concentration of 1 mg/mL. The positive control Z-Arg-Arg-Pro-Phe-His-Sta-Ile-His-Lys-(Boc)-Ome was tested at 10 μ M.160

Figure 5.5 Platelet-activating factor-acetylhydrolase (PAF-AH) inhibition by (A) gastric (G) and small intestinal digests (G + SI) of the gastrointestinal endogenous proteins, porcine trypsin (TRYP), human lysozyme (LYS), porcine salivary mucin (MUC) and human serum albumin (SA), and dietary protein chicken albumin (CA); and (B) <10 and <3 kDa fractions of the small intestinal digests. All of the samples were tested at the concentration of 1 mg/mL. The positive control methyl arachidonyl fluorophosphate (MAFP) was tested at 260 ng/mL.....162

Figure 5.6 Dipeptidyl peptidase IV (DPP-IV) inhibition by (A) gastric (G) and small intestinal digests (G + SI) of the gastrointestinal endogenous proteins, porcine trypsin (TRYP), human lysozyme (LYS), porcine salivary mucin (MUC) and human serum albumin (SA), and dietary protein chicken albumin (CA); and (B) <10 and <3 kDa fractions of the

small intestinal digests. All of the samples were tested at the concentration of 1 mg/mL. The positive control sitagliptin was tested at 100 μ M..... 164

Figure 5.7 Total antioxidant capacity by 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) inhibition by (A) gastric (G) and small intestinal digests (G + SI) of the gastrointestinal endogenous proteins, porcine trypsin (TRYP), human lysozyme (LYS), porcine salivary mucin (MUC) and human serum albumin (SA), and dietary protein chicken albumin (CA); and (B) <10 and <3 kDa fractions of the small intestinal digests. All of the samples and the positive control resveratrol were tested at the concentration of 1 mg/mL and the results are expressed in μ M trolox equivalents (TE). 166

Figure 5.8 2,2-diphenyl-1-picrylhydrazyl (DPPH) inhibition by (A) gastric (G) and small intestinal digests (G + SI) of the gastrointestinal endogenous proteins, porcine trypsin (TRYP), human lysozyme (LYS), porcine salivary mucin (MUC) and human serum albumin (SA), and dietary protein chicken albumin (CA); and (B) <10 and <3 kDa fractions of the small intestinal digests. All of the samples and the positive control resveratrol were tested at the concentration of 1 mg/mL..... 168

Figure 6.1 The *in vivo* and *in vitro* experimental design and methodologies used to study the generation of porcine gastrointestinal endogenous protein (GEP)-derived bioactive peptides in the stomach chyme and jejunal digesta of pigs, following gastrointestinal (GIT) digestion of a protein free diet. 206

Figure 6.2 Tris-tricine sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) analysis of the dialysed protein and peptide fractions precipitated from stomach chyme (SC1, SC2, and SC3) and jejunal digesta (JD1, JD2 and JD3) samples obtained from the growing pigs. **207**

Figure 6.3 ACE-I (Angiotensin-I converting enzyme) inhibition for the dialysed protein and peptide fractions precipitated from stomach chyme (SC1, SC2, and SC3) and jejunal digesta (JD1, JD2 and JD3) samples each obtained from three growing pigs and for the positive control captopril.**209**

Figure 6.4 FRAP (Ferric reducing antioxidant potential) for the dialysed protein and peptide fractions precipitated from stomach chyme (SC1, SC2, and SC3) and jejunal digesta (JD1, JD2 and JD3) samples each obtained from three growing pigs.**211**

Figure 6.5 DPPH (2,2-diphenyl-1-picrylhydrazyl) inhibition for the dialysed protein and peptide fractions precipitated from stomach chyme (SC1, SC2, and SC3) and jejunal digesta (JD1, JD2 and JD3) samples each obtained from three growing pigs and for the positive control (resveratrol).**212**

Figure 6.6 MLP (Microsomal lipid peroxidation) inhibition for the dialysed protein and peptide fractions precipitated from stomach chyme (SC1, SC2, and SC3) and jejunal digesta (JD1, JD2 and JD3) samples each obtained from three growing pigs and from the positive control resveratrol.**213**

List of Tables

Table 2.1 Examples of recently discovered bioactive peptides from dietary proteins or the food peptidome that are predicted to be released after simulated <i>in silico</i> or <i>in vitro</i> gastrointestinal tract (GIT) digestion.....	28
Table 2.2 Overview of experimental techniques used in the study reported here	52
Table 3.1 Gut endogenous and dietary proteins examined in the <i>in silico</i> study ¹	59
Table 3.2 Number (#) of potential bioactive peptides (per protein molecule) identified in the intact endogenous and dietary proteins and the A_0^1 and Y^2 values.....	67
Table 3.3. Number of potential bioactive peptides (per protein molecule) predicted to be released and A_D^1 value after gastric digestion of both gut endogenous proteins secreted in the mouth and stomach and selected dietary proteins based on an <i>in silico</i> digestion model.....	78
Table 3.4 Number of potential bioactive peptides (per protein molecule) predicted to be released and A_D^1 value after gastric plus small intestinal digestion for gut endogenous proteins secreted in the mouth and stomach and selected dietary proteins based on an <i>in silico</i> digestion model.....	81
Table 3.5 Number of potential bioactive peptides (per protein molecule) predicted to be released and A_D^1 value after small intestinal digestion for gut endogenous proteins secreted in the small intestine based on an <i>in silico</i> digestion model.....	86
Table 3.6 Amino acid ¹ sequences of bioactive peptides predicted to be released after mouth to ileum digestion of selected proteins based on an <i>in silico</i> digestion model.....	95

Table 3.7 Predicted quantity of bioactive peptides (mg/d) released after digestion of either dietary proteins or gut endogenous proteins in the gastrointestinal tract.....	98
Table 4.1 Details of human gastrointestinal endogenous proteins (GEP) studied in the <i>in silico</i> analysis	112
Table 4.2 The number of known DPP-IV inhibitory peptides and antioxidant peptides predicted to be released after simulated <i>in silico</i> gastrointestinal (SIGIT) digestion of selected GEP.	114
Table 4.3 Molecular weight (MW) and PeptideRanker scores of peptides selected for chemical synthesis and <i>in vitro</i> bioassays.	117
Table 4.4 The IC ₅₀ values for the two most active synthetic peptides among the total 19 peptides, RPCF and MIM.	121
Table 4.5 Estimated IC ₅₀ (± SD) of the antioxidant peptides CCK, RPCF and CRPK.	123
Table 4.6 Peptide subsequences matching with fragments within the intact novel peptides investigated in the present study (Data collated from BIOPEP (BIOPEP, 2015; Minkiewicz et al., 2008b).	127
Table 5.1 Gastrointestinal endogenous proteins (GEP) and dietary protein examined in the <i>in vitro</i> study.	147
Table 5.2 The protein content of the <i>in vitro</i> gastric (G) and small intestinal digests (G + SI) of the gastrointestinal endogenous proteins, porcine trypsin (TRYP), human lysozyme (LYS), porcine salivary mucin (MUC) and human serum albumin (SA), and dietary protein chicken albumin (CA).	155

Table 5.3 Gastrointestinal endogenous proteins (GEP)-derived peptide sequences found in the <3 and <10 kDa fractions of the <i>in vitro</i> small intestinal digests of lysozyme and serum albumin. The samples were analyzed using electrospray ionization time of flight mass spectrometry (ESI-TOF MS).	170
Table 6.1 Ingredient composition of the basal and experimental diet (g/kg dry matter).....	198
Table 6.2 The protein content of the dialysed protein and peptide fractions precipitated from stomach chyme (SC1, SC2, and SC3) and jejunal digesta (JD1, JD2 and JD3).	208
Table 6.3 Parent gastrointestinal endogenous proteins (GEP) that released the peptide sequences that were identified from the dialysed protein and peptide fractions precipitated from stomach chyme (SC) and jejunal digesta (JD) of growing pigs fed a protein-free diet. The samples were analysed using electrospray ionization time-of-flight liquid chromatography tandem mass spectrometry (ESI-TOF LC-MS/MS)..	215
Table 6.4 Gastrointestinal endogenous protein (GEP)-derived peptide sequences that were identified from the dialysed protein and peptide fractions precipitated from stomach chyme (SC3) and jejunal digesta (JD1 and JD3) of growing pigs fed a protein-free diet. The samples were analysed using electrospray ionization time-of-flight liquid chromatography tandem mass spectrometry (ESI-TOF LC-MS/MS).	218

List of Publications

Note: All of my publications have Lakshmi A. Dave as my author name

- **Dave, L. A.,** Hayes, M., Mora, L., Montoya, C. A., Moughan, P. J., & Rutherford, S M. (2016). Gastrointestinal endogenous protein-derived bioactive peptides: An *in vitro* study of their gut modulatory potential. *International Journal of Molecular Sciences*, 17(4), 482. doi:10.3390/ijms17040482.
- **Dave, L. A.,** Hayes, M., Rutherford, S. M., & Moughan, P. J. (2016). Novel Dipeptidyl Peptidase IV Inhibitory and Antioxidant Peptides Derived from Human Gastrointestinal Endogenous Proteins. *International Journal of Peptide Research and Therapeutics*, 22, 355. doi:10.1007/s10989-016-9515-y
- **Dave, L. A.,** Hayes, M., Montoya, C. A., Rutherford, S. M., & Moughan, P. J. (2015). Human gut endogenous proteins as a potential source of angiotensin-I-converting enzyme (ACE-I)-, renin inhibitory and antioxidant peptides. *Peptides*, 76, 30-44. doi: 10.1016/j.peptides.2015.11.003
- **Dave, L. A.,** Montoya, C. A., Rutherford, S M., & Moughan, P. J. (2014). Gastrointestinal endogenous proteins as a source of bioactive peptides - An *in silico* study. *PLoS ONE*, 9(6), e98922. doi: 10.1371/journal.pone.0098922

